One study used radiomics approach to evaluate immune infiltration of tumors and proved that radiomics signature is beneficial to predict clinical outcomes in patients treated with anti-programmed cell death protein 1 (PD-1) or anti-programmed death-ligand 1 (PD-L1) immunotherapy.[57] A small retrospective study explored the efficacy of radiomics features from ADC to monitor treatment response of bone metastases from PCa, and the findings indicated that the strategy might be utilized as a complement to average ADC values for treatment monitoring.[58]. This evidence concerns the gene PDCD1 and posterior cortical atrophy.